LDS/Medical Tests/Common Variable Immunodeficiency Confirmation Panel, Flow

Common Variable Immunodeficiency Confirmation Panel, Flow

B-cells are central to humoral immunity and play a critical role in antibody production. Common variable immunodeficiency (CVID) is a primary immunodeficiency disorder characterized by defective B-cell differentiation and impaired immunoglobulin production. This leads to hypogammaglobulinemia and increased susceptibility to recurrent infections, autoimmunity, chronic lung disease, and malignancy.

CVID is one of the most common clinically significant primary immunodeficiencies, affecting approximately 1 in 25,000 individuals. Although the exact cause is heterogeneous, both genetic and environmental factors contribute. Mutations in CD19, ICOS, and TNFRSF13B (TACI) genes are among the best-characterized molecular defects. Up to 20% of patients report a family history of selective IgA deficiency or antibody deficiency, suggesting a shared pathogenic background.

The disorder typically presents between 20 and 45 years of age with recurrent sinopulmonary infections (pneumonia, sinusitis, otitis media). Non-infectious complications, including autoimmune cytopenias (ITP, hemolytic anemia), chronic diarrhea, malabsorption, and lymphoma, are common and impact prognosis.

Diagnosis is based on persistently low serum IgG with low IgA and/or IgM levels and poor response to vaccines, after excluding secondary causes of hypogammaglobulinemia. Flow cytometry provides additional insight by characterizing B-cell subsets, enabling immunophenotypic classification of CVID. Various systems (e.g., Freiburg, Paris, EUROclass) categorize patients by proportions of class-switched memory B cells (CD27+IgD–), transitional B cells, and CD21low B cells, which correlate with clinical outcomes and risk of complications such as splenomegaly and granulomatous disease.

  • Aids the diagnosis and classification of Common variable immunodeficiency
  • Guides treatment planning and immunoglobulin replacement monitoring
  • Identifies underlying immune dysfunction contributing to infection or autoimmunity

Flow cytometric analysis in suspected CVID focuses on B-cell subset characterization.

  1. Defining abnormality: Reduction in class-switched memory B cells (CD27+IgD–), often accompanied by decreased total memory B cells (CD27+).
  2. Transitional (CD38++IgM++) and naïve (CD27–IgD+) B cells may be increased, reflecting impaired maturation.
  3. CD21low B-cell expansion is associated with splenomegaly, granulomatous disease, and autoimmunity.
  4. T-cell and NK-cell counts are generally preserved, though mild CD4+ lymphopenia or reduced CD4/CD8 ratios may occur.

According to ESID/PAGID diagnostic criteria, markedly reduced class-switched memory B cells (<2% of total B cells) together with hypogammaglobulinemia supports a diagnosis of CVID. Interpretation must be integrated with clinical findings and immunoglobulin levels.

Subset Reference Range (% of lymphocytes)
CD3+ T cells 60–85%
CD4+ T cells 30–55%
CD8+ T cells 15–35%
CD19+ B cells 6–19%
CD16+56+ NK cells 5–20%
CD27+ memory B cells 15–35%
Switched memory B cells (CD27+IgD–) 7–18%
Flow cytometry using monoclonal antibodies targeting B-cell surface markers (CD19, CD27, IgD, CD38, CD21).

Whole blood (EDTA).

Stability

  • Ambient: 24 hrs. (for best cell viability and accurate subset analysis.)
  • Refrigerated: 24 hrs. (avoid prolonged refrigeration as some lymphocyte subsets, especially B cells, may decline.)
  • Frozen: Unacceptable
Serum immunoglobulins (IgG, IgA, IgM), IgG subclass quantification, BAFF-R expression (flow cytometry), Lymphocyte proliferation assays, TNFRSF13B (TACI) gene mutation analysis.
1 to 3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login